Comparative activities of the oxazolidinone AZD2563 and linezolid against selected recent North American isolates of Streptococcus pneumoniae

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 9, 2002, Pages 3094-3095

  Baum, Sue E ^a   Crawford, Sharon A ^a   McElmeel, M L ^a   Whitney, Cynthia G ^a   Jorgensen, James H ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DALFOPRISTIN PLUS QUINUPRISTIN; ERYTHROMYCIN; LEVOFLOXACIN; LINEZOLID; OXAZOLIDINE DERIVATIVE; PENICILLIN G; POSIZOLID; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; COMPARATIVE STUDY; CONTROLLED STUDY; DILUTION; DRUG ACTIVITY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE;

EID: 0036720617     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.9.3094-3095.2002     Document Type: Article

References (13)

1. Microbiological and pharmacodynamic considerations in the treatment of infection due to antimicrobial-resistant Streptococcus pneumoniae
2. Practice guidelines for the management of community-acquired pneumonia in adults
3. Antimicrobial resistance with Streptococcus pneumoniae in the United States, 1997-1998
4. Activity of linezolid against gram-positive cocci possessing genes conferring resistance to protein synthesis inhibitors
5. Management of infections caused by antibiotic-resistant Streptococcus pneumoniae
6. Management of community-acquired pneumonia in the era of pneumococcal resistance
7. Activity of linezolid against multi-resistant gram-positive bacteria from diverse hospitals in the United Kingdom
8. In vitro activity of selected cephalosporins and erythromycin against staphylococci and pneumococci isolated at 38 North American medical centers participating in the SENTRY antimicrobial surveillance program, 1997-1998
9. Ribosomal RNA is the target for oxazolidinones, a novel class of translational inhibitors
10. Emerging therapies for serious gram-positive bacterial infections: A focus on linezolid
11. Linezolid resistance in a clinical isolate of Staphylococcus aureus
12. Increasing prevalence of multidrug resistant Strepococcus pneumoniae in the United States